Mizuho Securities analyst Uy Ear has maintained their bullish stance on ALKS stock, giving a Buy rating on September 26. Uy Ear has given his ...

citing the potential of ALKS-2680 as a leading treatment for narcolepsy. Furthermore, Alkermes is considering further development of ALKS-2680 for idiopathic hypersomnia (IH), based on the unmet ...

Mizuho expressed confidence in the potential of ALKS-2680 to become a leading treatment for narcolepsy ... development of ALKS-2680 for idiopathic hypersomnia (IH), based on the unmet need ...

Presentation Details Oral Presentation Title: Safety and Efficacy of KP1077 in a Phase 2, Placebo-Controlled, Double-Blind, Randomized Withdrawal Study in Patients with Idiopathic Hypersomnia ...

Idiopathic hypersomnia (IH) is a rare sleep disorder characterized by excessive daytime ... have been misdiagnosed, or are not currently seeking treatment. KP1077 (serdexmethylphenidate or SDX) is ...

The positive phase 3 results showed improved lung function with nerandomilast vs placebo at 52 weeks in idiopathic pulmonary ... signaling a potential new treatment option for a condition that ...

Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial ...

This pivotal document, a product of the Illuminate Hypersomnia initiative, offers a comprehensive view of the lived experiences and treatment aspirations of individuals with IH. A 360-degree ...